SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In
 
We’re going down soon, to move to a new Data Center today.  We’ll be up ASAP.  Sorry.

Moderna, Inc. 
 MA
  SEC # 1682852


        
    Click to view...      Registrant      About      Filings      Files      Relationships      Names    
  Topics  
    Web       

207  Topics
Topic emoji
 within the 

Show:   Most-Recent Document   All Documents   And:   Exhibits  

 As Of  Filing  Doc.  Page    Title Docs.
  In ascending order
5/5/23S-3ASR1About the Company
1About This Prospectus
2/23/2410-K1Agreements
3/21/24DEF 14A1Appendix A
1Appendix B
1Audit Committee Report
1Back to Contents
1CEO Pay Ratio
1Certain Relationships and Related Party Transactions
2/23/2410-K1Collaboration
3/21/24DEF 14A1Compensation and Talent Committee Report
8/3/2310-Q1Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022
5/4/2310-Q1Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023
11/3/2310-Q1Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022
1Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022
8/3/2310-Q1Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022
5/4/2310-Q1Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023
5/4/2310-Q1Condensed Consolidated Statements of Comprehensive
11/3/2310-Q1Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2023 and 2022
8/3/2310-Q1Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2023 and 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2024 and 2023
11/3/2310-Q1Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022
8/3/2310-Q1Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022
5/4/2310-Q1Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023
11/3/2310-Q1Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022
8/3/2310-Q1Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2023 and 2022
5/4/2310-Q1Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2023 and 2022
5/2/24New Filing!  10-Q1Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2024 and 2023
2/23/2410-K1Consolidated Balance Sheets as of December 31, 2023 and 2022
1Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022, and 2021
1Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2023, 2022, and 2021
1Consolidated Statements of Operations for the years ended December 31, 2023, 2022, and 2021
1Consolidated Statements of Stockholders' Equity for the years ended December 31, 2023, 2022, and 2021
5/2/24New Filing!  10-Q1Controls and Procedures
5/5/23S-3ASR1Description of Capital Stock
1Description of Debt Securities
1Description of Units
1Description of Warrants
3/21/24DEF 14A1Director Compensation
1Employment Arrangements with our NEOs
1Equity-Related Policies and Practices
1ESG Topics
1Executive Compensation
1Executive Compensation Tables
1Executive Summary
5/2/24New Filing!  10-Q1Exhibits
5/5/23S-3ASR1Experts
5/2/24New Filing!  10-Q1Financial Statements (Unaudited)
3/21/24DEF 14A1Governance
1Governance of Executive Compensation Program
5/4/2310-Q1Income for the three months ended March 31, 2023 and 2022
5/5/23S-3ASR1Incorporation of Certain Information by Reference
3/21/24DEF 14A1Information about the 2024 Annual Meeting of Shareholders
5/5/23S-3ASR1Legal Matters
5/2/24New Filing!  10-Q1Legal Proceedings
3/21/24DEF 14A1Letter from the Compensation and Talent Committee
1Management
5/2/24New Filing!  10-Q1Management's Discussion and Analysis of Financial Condition and Results of Operations
11/3/2310-Q1Note
5/2/24New Filing!  10-Q1Note 10
1Note 11
2/23/2410-K1Note 12
5/2/24New Filing!  10-Q1Note 13
11/3/2310-Q1Note 14
1Note 15
2/23/2410-K1Note 2
5/2/24New Filing!  10-Q1Note 3
2/23/2410-K1Note 5
1Note 6
5/2/24New Filing!  10-Q1Note 7
11/3/2310-Q1Note 8
1Note 9
5/2/24New Filing!  10-Q1Notes to Condensed Consolidated Financial Statements
2/23/2410-K1Notes to Consolidated Financial Statements
1Ote 2
5/2/24New Filing!  10-Q1Ote 5
3/21/24DEF 14A1Other Compensation Policies and Practices
1Other Employee Benefits & Perquisites
11/3/2310-Q1Other Information
3/21/24DEF 14A1Overview of Executive Compensation Program
1Pay Versus Performance
5/5/23S-3ASR1Plan of Distribution
1Power of Attorney (included in the signature pages to this registration statement)
2/23/24S-81Power of Attorney (included on signature page)
3/21/24DEF 14A1Primary Elements of Executive Compensation Program
1Proposal No. 1: Election of Directors
1Proposal No. 2: Non-binding Advisory Vote to Approve the Compensation of our Named Executive Officers
1Proposal No. 3: Ratification of Appointment of Independent Registered Public Accounting Firm
1Proposal No. 4: Amend Our Certificate of Incorporation to Provide Shareholders the Right to Call a Special Meeting
1Proposal No. 5: Amend Our Certificate of Incorporation to Reflect New Delaware Law Provisions Allowing for Officer Exculpation
1Proxy Summary
5/2/24New Filing!  10-Q1Quantitative and Qualitative Disclosures about Market Risk
2/23/2410-K1Report of Independent Registered Public Accounting Firm
5/2/24New Filing!  10-Q1Risk Factors
3/21/24DEF 14A1Security Ownership of Certain Beneficial Owners and Management
5/5/23S-3ASR1Selling Securityholders
5/2/24New Filing!  10-Q1Signatures
5/5/23S-3ASR1Special Note Regarding Forward-Looking Statements
11/3/2310-Q1Table of Content
5/2/24New Filing!  10-Q1Table of Contents
1Unregistered Sales of Equity Securities and Use of Proceeds
5/5/23S-3ASR1Use of Proceeds
1Where You Can Find More Information
2/23/2410-K1101
1102
1104
1105
1106
1107
1109
1110
1140
1141
1143
1144
1145
1148
1149

Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 11, 7:16:22.3am ET